Brian Cheng Analyst Performance

Biotech Analyst at JPMorgan Chase & Co.

Brian Cheng is a stock analyst at JPMorgan Chase & Co. in the medical sector, covering 14 publicly traded companies. Over the past year, Brian Cheng has issued 16 stock ratings, including buy, hold, and sell recommendations. While full access to Brian Cheng's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Brian Cheng's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 18 Last 3 Years
Buy Recommendations: 66.67% 12 Buy Ratings
Companies Covered: 14 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	66.7%	12 ratings
Hold	27.8%	5 ratings
Sell	5.6%	1 ratings

Out of 18 total stock ratings issued by Brian Cheng at JPMorgan Chase & Co., the majority (66.7%) have been Buy recommendations, followed by 27.8% Hold and 5.6% Sell.

Best & Worst Calls

Best Call
000.0%
PSTX
Feb 2022
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
00.0%
PSTX
Jan 2022
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	14 companies

Brian Cheng, an analyst at JPMorgan Chase & Co., currently covers 14 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 14 companies	100.0%

Brian Cheng of JPMorgan Chase & Co. specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 13 companies	92.9%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	7.1%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
CRSP CRISPR Therapeutics	9/18/2025	Initiated Coverage	$59.07	$70.00	Overweight
ROIV Roivant Sciences	9/18/2025	Boost Price Target	$15.42	$20.00	Overweight
PGEN Precigen	8/15/2025	Upgrade	$1.85		Neutral
IMVT Immunovant	8/12/2025	Lower Price Target	$15.26	$37.00	Overweight
IMNM Immunome	8/7/2025	Lower Price Target	$9.87	$22.00	Overweight
ALLO Allogene Therapeutics	8/4/2025	Reiterated Rating	$1.08		Neutral
BPMC Blueprint Medicines	6/2/2025	Reiterated Rating	$127.71	$129.00	Neutral
ITOS iTeos Therapeutics	5/13/2025	Downgrade	$8.02	$8.00	Neutral
CGON CG Oncology	5/2/2025	Initiated Coverage	$27.74	$41.00	Overweight
AAPG Ascentage Pharma Group International	3/27/2025	Initiated Coverage	$18.37		Overweight
ITOS iTeos Therapeutics	3/6/2025	Lower Price Target	$7.11	$15.00	Overweight
PTGX Protagonist Therapeutics	3/4/2025	Boost Price Target	$38.50	$57.00	Overweight
NTLA Intellia Therapeutics	2/28/2025	Reiterated Rating	$10.86	$13.00	Neutral
PTGX Protagonist Therapeutics	2/4/2025	Boost Price Target	$37.66	$53.00	Overweight
BPMC Blueprint Medicines	2/4/2025	Boost Price Target	$112.35	$129.00	Overweight
CRGX CARGO Therapeutics	1/30/2025	Downgrade	$13.19		Underweight

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.